| Irene Grias, DO | |
|
11511 Canterwood Blvd Nw, Ste 145, Gig Harbor, WA 98332-5813 | |
| (253) 530-2940 | |
| (253) 530-2970 |
| Full Name | Irene Grias |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 11511 Canterwood Blvd Nw, Gig Harbor, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760688519 | NPI | - | NPPES |
| 327409 | Other | WA | STATE L&I |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | OP60460467 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Anthony Hospital | Gig harbor, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
Republican foes of the overhaul came out of the confrontation with only a tweak to income verification rules for those seeking subsidies to buy coverage on the new health insurance exchanges. The agreement created a new budget deadline, however, requiring lawmakers to return to the table to reach a long-term deficit reduction agreement by Dec. 1
While we sleep, the brain produces particular activation patterns. When two of these patterns - slow oscillations and sleep spindles - gear into each other, previous experiences are reactivated.
Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.
Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting.
Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche's investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.
› Verified 3 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
Republican foes of the overhaul came out of the confrontation with only a tweak to income verification rules for those seeking subsidies to buy coverage on the new health insurance exchanges. The agreement created a new budget deadline, however, requiring lawmakers to return to the table to reach a long-term deficit reduction agreement by Dec. 1
While we sleep, the brain produces particular activation patterns. When two of these patterns - slow oscillations and sleep spindles - gear into each other, previous experiences are reactivated.
Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.
Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting.
Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche's investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Irene Grias, DO 11511 Canterwood Blvd Nw, Ste 145, Gig Harbor, WA 98332-5813 Ph: (253) 530-2940 | Irene Grias, DO 11511 Canterwood Blvd Nw, Ste 145, Gig Harbor, WA 98332-5813 Ph: (253) 530-2940 |
News Archive
Republican foes of the overhaul came out of the confrontation with only a tweak to income verification rules for those seeking subsidies to buy coverage on the new health insurance exchanges. The agreement created a new budget deadline, however, requiring lawmakers to return to the table to reach a long-term deficit reduction agreement by Dec. 1
While we sleep, the brain produces particular activation patterns. When two of these patterns - slow oscillations and sleep spindles - gear into each other, previous experiences are reactivated.
Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.
Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting.
Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche's investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.
› Verified 3 days ago
Ms. Jennifer Nadine Jaggi, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11505 Burnham Drive, Suite 302, Gig Harbor, WA 98332 Phone: 253-313-5997 Fax: 253-313-5179 | |
Dr. Michael Allan Bidus, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11511 Canterwood Blvd Nw Ste 100, Gig Harbor, WA 98332 Phone: 253-382-8150 Fax: 253-382-8155 | |
Orestes Molina, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4545 Point Fosdick Dr Nw, Gig Harbor, WA 98335 Phone: 253-530-8122 | |
Cynthia Marie Mosbrucker, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11505 Burnham Drive, Suite 302, Gig Harbor, WA 98332 Phone: 253-313-5997 Fax: 253-313-5197 | |
Dagnie C Lamb, MD, MCR Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4545 Point Fosdick Dr # 130, Gig Harbor, WA 98335 Phone: 253-530-8122 Fax: 253-530-8139 | |
Moritz Christian Bartels, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4545 Point Fosdick Dr Nw, Gig Harbor, WA 98335 Phone: 253-530-8122 |